AbbVie Inc. (ABBV) News
Track canonical SquawkNews coverage tagged to ABBV, AbbVie Inc.. This hub brings together deduplicated headlines about united states, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 125 indexed stories across 46 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
AbbVie and Iambic announce AI-driven drug discovery collaboration
AbbVie announced a collaboration with Iambic aimed at accelerating AI-driven drug discovery.
EQUITY | Sep 21, 2026, 12:38 PM UTC
M
AbbVie signs multi-year AI drug discovery collaboration with Iambic
AbbVie announced a multi-year collaboration with Iambic to use its AI platform, including Enchant v3, to accelerate small-molecule discovery across immunology, neuroscience and oncology. Iambic will receive an upfront pa
EQUITY | Sep 21, 2026, 12:01 PM UTC
L
ABBV - AbbVie and Iambic Announce Collaboration to Accelerate AI -driven Drug Discovery
ABBV - AbbVie and Iambic Announce Collaboration to Accelerate AI -driven Drug Discovery
NEWS | Sep 21, 2026, 12:01 PM UTC
M
AbbVie and Iambic announce multi-year AI drug discovery collaboration
AbbVie and clinical-stage biotech Iambic said they entered a multi-year collaboration to accelerate drug discovery using Iambic’s AI-driven platform.
EQUITY | Sep 21, 2026, 12:01 PM UTC
M
ADARx Pharmaceuticals plans IPO sale of 21.9M shares
ADARx Pharmaceuticals said it plans to sell nearly 21.9 million shares in its IPO at $15 to $17 each.
EQUITY | Sep 21, 2026, 11:17 AM UTC
H
ABBV - AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026
ABBV - AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026
GEOPOLITICS | Sep 18, 2026, 12:30 PM UTC
L
ABBV - AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
ABBV - AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
NEWS | Sep 17, 2026, 12:30 PM UTC
L
ABBV - Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications
ABBV - Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications
NEWS | Sep 17, 2026, 12:01 PM UTC
H
This Small Biotech’s Cancer Drug Could Reach $1.3 Billion In Peak Sales
Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL ) received a bullish initiation from William Blair, which sees a potential blockbuster opportunity for the biotech company's lead cancer drug, azenosertib. William Blair analys
LIVE | Sep 16, 2026, 05:38 PM UTC
L
ABBV: Robust pipeline and strategic deals drive growth in immunology, neuroscience, and oncology
Strong growth in immunology, neuroscience, and oncology is driven by a robust pipeline, strategic acquisitions like Apogee, and innovative combination therapies. Market expansion is expected in atopic dermatitis, asthma,
NEWS | Sep 15, 2026, 03:59 PM UTC
L
ABBV: Immunology and neuroscience drive growth, with pipeline innovation and strategic deals fueling expansion
Strong growth in immunology and neuroscience has offset major revenue erosion, with a robust pipeline spanning immunology, oncology, CNS, and obesity. Strategic acquisitions like Apogee and innovative combination therapi
NEWS | Sep 15, 2026, 03:58 PM UTC
L
ABBV: Pipeline innovation and strategic deals fuel robust growth in immunology and neuroscience
Strong pipeline momentum is driving growth across immunology, oncology, and neuroscience, with major late-stage assets and innovative combination therapies advancing. Strategic acquisitions like Apogee and new AI initiat
NEWS | Sep 15, 2026, 03:07 PM UTC
L
ABBV - AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign
ABBV - AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign
NEWS | Sep 15, 2026, 12:30 PM UTC
L
AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign
NORTH CHICAGO, Ill., Sept. 15, 2026 // -- AbbVie (NYSE:ABBV), a global pharmaceutical leader, and the PGA TOUR today announced a partnership naming AbbVie the Official Pharmaceutical Sponsor of the PGA TOUR and the 2026
NEWS | Sep 15, 2026, 12:30 PM UTC
L
ABBV - Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit
ABBV - Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit
NEWS | Sep 15, 2026, 12:01 PM UTC
H
Catalyst Watch: FOMC blockbuster, Salesforce event, and 24-hour trading talk
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week.Monday - September 14Tuesday - September
CENTRAL_BANK | Sep 11, 2026, 07:01 PM UTC
L
AbbVie declares quarterly cash dividend of $1.73 per share
AbbVie declared a quarterly cash dividend of $1.73 per share, according to TradingView News. The announcement is tied to AbbVie Inc. listed on the NYSE as ABBV.
EQUITY | Sep 10, 2026, 06:48 PM UTC
L
AbbVie says Qulipta hit Phase 3 goal for menstrual migraine
AbbVie said Qulipta achieved the main goal of a Phase 3 trial targeting menstrual migraine. The trial tested a sharper, more targeted treatment schedule, with results cited by the company as meeting the main goal.
EQUITY | Sep 10, 2026, 06:21 PM UTC
L
HSBC maintains buy on AbbVie, raises target to $315
Benzinga/TradingView reports that HSBC raised its AbbVie price target to $315 from $300 and maintained a Buy rating.
EQUITY | Sep 10, 2026, 02:21 PM UTC
M
AbbVie’s atogepant meets primary and secondary endpoints in phase 3 trial
AbbVie said its migraine drug atogepant met primary and secondary endpoints in a phase 3 trial for preventive treatment of menstrual migraines. The study reduced migraine days by 1.2 days on average versus 0.4 days.
EQUITY | Sep 10, 2026, 01:38 PM UTC
M
AbbVie’s atogepant meets late-stage goal in menstrual migraine study
AbbVie said its migraine treatment atogepant, branded as Qulipta in the U.S., reduced migraine days associated with the menstrual period in a late-stage study.
EQUITY | Sep 10, 2026, 01:38 PM UTC
M
AbbVie migraine treatment meets late-stage study main goal
AbbVie said its late-stage study of its preventive menstrual migraine treatment in adults met the main goal.
EQUITY | Sep 10, 2026, 01:01 PM UTC
L
ABBV - AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine
ABBV - AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine
EQUITY | Sep 10, 2026, 12:56 PM UTC
L
25 dividend stocks to watch as market sentiment turns negative
Dividend-paying stocks gained renewed momentum Wednesday as investors shifted toward safety amid a slide in broader market averages.The blue-chip Dow Jones Industrial Average TVC:DJI dropped to a new one-month low while
ENERGY | Sep 09, 2026, 04:51 PM UTC
L
ABBV: Strong immunology growth and innovative oncology assets set the stage for long-term expansion
Immunology assets SKYRIZI and RINVOQ are driving growth with new indications and strong data, while oncology and neuroscience pipelines advance with innovative therapies and strategic capital allocation. Key milestones i
EQUITY | Sep 09, 2026, 04:12 PM UTC
L
ABBV: Immunology, oncology, and neuroscience pipelines advance with strong data and strategic investments
Immunology assets SKYRIZI and RINVOQ continue to outperform, with new indications and combination therapies driving growth. Oncology and neuroscience pipelines advance with differentiated assets, while disciplined capita
EQUITY | Sep 09, 2026, 03:26 PM UTC
H
AbbVie confirms 2026 EPS guidance alongside etentamig Phase 3 gains
AbbVie reported Phase III CERVINO results for etentamig, citing higher ORR, lower progression risk and improved 12-month OS, and confirmed a blood-cancer primary endpoint. The company reaffirmed 2026 EPS guidance.
EARNINGS | Sep 07, 2026, 11:22 AM UTC
M
AbbVie reports 74% response rate for Etentamig in pivotal trial
AbbVie said Etentamig delivered a 74% overall response rate in a pivotal blood-cancer trial, while standard treatments managed 45.7%. Shares were priced at $260.445.
CENTRAL_BANK | Sep 03, 2026, 09:36 PM UTC
L
News On Apogee Therapeutics Inc. (APGE) Now Under ABBV
News On Apogee Therapeutics Inc. (APGE) Now Under ABBV
EQUITY | Sep 03, 2026, 09:09 PM UTC
M
AbbVie announces positive Phase 3 CERVINO topline for etentamig
AbbVie said its Phase 3 CERVINO trial for investigational etentamig in relapsed/refractory multiple myeloma met both primary endpoints, with etentamig achieving higher objective response results in topline findings.
EQUITY | Sep 03, 2026, 01:52 PM UTC
M
AbbVie’s etentamig meets dual primary endpoints in Phase 3 blood cancer study
AbbVie said its blood-cancer drug etentamig met dual primary endpoints in a Phase 3 study, including a significantly higher objective response rate and improvements in progression-free survival versus standard available
CENTRAL_BANK | Sep 03, 2026, 01:42 PM UTC
M
AbbVie’s blood cancer drug meets late-stage trial goals
AbbVie said its drug for a type of blood cancer met the main goals of a late-stage trial.
EQUITY | Sep 03, 2026, 01:28 PM UTC
H
AbbVie affirms FY2026 adjusted EPS guidance at $13.87-$14.07
AbbVie affirms FY2026 adjusted EPS guidance of $13.87-$14.07 versus a $14.08 analyst estimate.
EARNINGS | Sep 03, 2026, 01:17 PM UTC
H
AbbVie reaffirms Q3 adjusted EPS guidance at $3.84-$3.88
AbbVie has affirmed its Q3 adjusted EPS guidance of $3.84-$3.88, unchanged from its prior range, versus a $3.84 analyst estimate.
EARNINGS | Sep 03, 2026, 01:17 PM UTC
M
AbbVie reports positive topline from Phase 3 CERVINO trial
AbbVie says Phase 3 CERVINO TOPLINE results are positive, with etentamig showing improved response rate and progression-free survival in relapsed/refractory multiple myeloma.
CENTRAL_BANK | Sep 03, 2026, 01:17 PM UTC
H
AbbVie completes $10.9 billion Apogee acquisition
AbbVie completed its $10.9 billion acquisition of Apogee Therapeutics and reaffirmed 2026 adjusted diluted EPS guidance.
EARNINGS | Sep 03, 2026, 12:54 PM UTC
M
AbbVie completes acquisition of Apogee Therapeutics
AbbVie completed its acquisition of Apogee Therapeutics.
MNA | Sep 03, 2026, 12:35 PM UTC
L
AbbVie to present at Morgan Stanley 24th Global Healthcare Conference
AbbVie plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference.
EQUITY | Sep 03, 2026, 12:05 PM UTC
L
AbbVie to participate in Morgan Stanley 24th Global Healthcare conference
AbbVie will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, with management in a fireside chat at 9:00 a.m. Central time.
EQUITY | Sep 03, 2026, 12:05 PM UTC
L
ABBV - Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care
ABBV - Allergan Aesthetics Unveils the Layered Beauty Report, Advancing the Global Conversation Around Aesthetic Care
EQUITY | Sep 02, 2026, 12:02 PM UTC
L
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
NEW YORK, Sept. 1, 2026 /CNW/ -- Equity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare. Multiple market-research firms size it at ro
FX | Sep 01, 2026, 03:38 PM UTC
L
Allergan Aesthetics expands SkinMedica line with Barrier Calming Cream
Allergan Aesthetics, an AbbVie company, says it launched SkinMedica Barrier Calming Cream, a restorative moisturizer designed to soothe skin and help restore and fortify skin.
EQUITY | Sep 01, 2026, 12:05 PM UTC
L
ABBV - SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings
ABBV - SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings
EQUITY | Sep 01, 2026, 12:05 PM UTC
L
America Fell in Love With Filler. Then Came the Great Deflate — WSJ
America Fell in Love With Filler. Then Came the Great Deflate — WSJ
EQUITY | Aug 31, 2026, 06:40 PM UTC
M
AbbVie submits EMA application for Skyrizi in adult Crohn’s
AbbVie submitted an EMA application for Skyrizi subcutaneous induction in adult Crohn's disease.
EQUITY | Aug 27, 2026, 06:33 AM UTC
L
AbbVie submits EMA regulatory application for SKYRIZI Crohn’s induction
AbbVie submitted a regulatory application to the EMA for SKYRIZI subcutaneous induction in adults with moderately to severely active Crohn’s disease.
EQUITY | Aug 27, 2026, 06:00 AM UTC
H
AbbVie to Present New Lung Cancer Data at WCLC 2026
AbbVie (ABBV) says it will present new data at the WCLC 2026 show, highlighting innovation across its lung cancer pipeline; no details on results or magnitude were supplied.
EARNINGS | Aug 21, 2026, 11:45 AM UTC
L
ABBV - AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
ABBV - AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
EQUITY | Aug 18, 2026, 12:02 PM UTC
L
BNP Paribas Maintains Neutral on AbbVie, Raises Price Target to $247
BNP Paribas analyst Navann Ty maintains AbbVie (NYSE: ABBV ) with a Neutral and raises the price target from $218 to $247.
EQUITY | Aug 11, 2026, 05:55 PM UTC
H
Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'
New York Governor Kathy Hochul (D) said President Donald Trump’ s decision to end a Medicare subsidy program will raise prescription drug costs for about 1.3 million New Yorkers, arguing seniors should not have to bear t
GEOPOLITICS | Aug 06, 2026, 07:41 AM UTC
H
AbbVie Uses Note Offering For Apogee Acquisition
AbbVie funds Apogee Therapeutics acquisition
MNA | Aug 04, 2026, 01:02 PM UTC
M
Abbvie Launches Benchmark Debt Offering
Abbvie issues debt in 9 parts
EQUITY | Aug 04, 2026, 12:10 PM UTC
L
ABBV - Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Musc
ABBV - Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence
REGULATION | Aug 04, 2026, 12:01 PM UTC
H
AbbVie Stock Falls as Guidance Cut Overshadows Strong Q2 Earnings Beat
AbbVie Inc. (NYSE: ABBV ) shares are retreating Friday as a modest reduction to full-year adjusted EPS guidance that pushed the midpoint beneath the analyst target proved enough to sour the market’s mood. Here’s what you
EARNINGS | Jul 31, 2026, 02:16 PM UTC
H
AbbVie Sees Q3 Adjusted EPS $3.84-$3.88
AbbVie expects Q3 adjusted EPS between $3.84 and $3.88
EARNINGS | Jul 31, 2026, 01:33 PM UTC
H
AbbVie Sees Q3 Net Revenues of $17.2B
AbbVie forecasts Q3 revenue
EARNINGS | Jul 31, 2026, 01:31 PM UTC
H
AbbVie trims 2026 profit forecast
AbbVie cuts 2026 profit forecast
EARNINGS | Jul 31, 2026, 01:30 PM UTC
L
ABBV AbbVie exec notes expect skyrizi global annual revenue of $21.7B, an increase of $100M vs previous forecast - conf call
ABBV AbbVie exec notes expect skyrizi global annual revenue of $21.7B, an increase of $100M vs previous forecast - conf call
EQUITY | Jul 31, 2026, 01:27 PM UTC
H
AbbVie Q2 Revenue Beats Estimates
AbbVie Q2 revenue exceeds estimates
EARNINGS | Jul 31, 2026, 11:56 AM UTC
H
AbbVie Lowers FY2026 Adj EPS Guidance from $14.08-$14.28 to $13.87-$14.07 vs $14.08 Est
AbbVie (NYSE: ABBV ) lowers FY2026 Adj EPS guidance from $14.08-$14.28 to $13.87-$14.07 vs $14.08 analyst estimate..
EARNINGS | Jul 31, 2026, 11:52 AM UTC